Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Recent Advances in Pulmonary Embolism and Thrombosis: 2nd Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Advances in Pulmonary Embolism and Thrombosis: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".

Deadline for manuscript submissions: 25 April 2026 | Viewed by 776

Special Issue Editors

Dr. Andrea Boccatonda

E-Mail Website
Guest Editor
1. Internal Medicine, Bentivoglio Hospital, AUSL Bologna, 40010 Bologna, Italy
2. Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
Interests: critical care medicine; intensive care medicine; emergency treatment; embolism and thrombosis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Elena Campello

E-Mail Website
Guest Editor
Internal Medicine, Hemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED), Padova University Hospital, 35121 Padova, Italy
Interests: hematology; thrombosis; coagulation

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to the Special Issue entitled “Recent Advances in Pulmonary Embolism and Thrombosis: 2nd Edition”. This is one new edition; we published 11 papers in the first edition. For more details, please visit: https://www.mdpi.com/journal/jcm/special_issues/627ZWHN1UZ.

Pulmonary embolism (PE) and venous thromboembolism are serious conditions that involve the formation of blood clots in the lungs or other parts of the body. Anticoagulant therapy remains the mainstay of treatment for venous thrombosis. In cases where anticoagulation alone is insufficient or contraindicated, interventional procedures, such as catheter-directed thrombolysis or surgical embolectomy, may be considered. These procedures aim to remove or dissolve clots, restoring blood flow and preventing further complications.

Despite the advances in the diagnosis and treatment of pulmonary embolism and thrombosis that have been made over recent years, challenges remain in the management of PE and thrombosis. These include prevention, treatment, and management for patients with pulmonary embolism and thrombosis; continued research and innovation in this field will further enhance our understanding and management of these conditions, ultimately leading to better outcomes for patients. This Special Issue aims to report the latest research on pulmonary embolism and thrombosis. We would like to cordially invite you to submit your manuscripts for review and publication in the Journal of Clinical Medicine to improve clinical outcomes as well as ensure optimal short- and long-term management.

Dr. Andrea Boccatonda
Prof. Dr. Elena Campello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary embolism
  • embolism and thrombosis
  • thrombus aspiration for pulmonary embolism
  • deep vein thrombosis
  • venous thromboembolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 289 KB  
Article
Malignancy-Associated Pulmonary Embolism: Mortality, Recurrence, and Bleeding Risks
by Daniela Maria Nemțuț, Florica Voiță-Mekeres, Ruxandra Ulmeanu, Florian Bodog, Grațiela Avram, Ioan Bogdan Voiță, Nuțu Cristian Voiță, Mariana Racoviță, Alexandru Catalin Motofelea and Lavinia Davidescu
J. Clin. Med. 2025, 14(21), 7819; https://doi.org/10.3390/jcm14217819 - 4 Nov 2025
Viewed by 598
Abstract
Background/Objectives: Pulmonary embolism (PE) remains a leading cause of morbidity and mortality, with outcomes influenced by patient demographics, comorbidities, and anticoagulation strategy. While vitamin K antagonists (VKA) have been standard therapy, direct oral anticoagulants (DOACs) are increasingly adopted, yet real-world data in [...] Read more.
Background/Objectives: Pulmonary embolism (PE) remains a leading cause of morbidity and mortality, with outcomes influenced by patient demographics, comorbidities, and anticoagulation strategy. While vitamin K antagonists (VKA) have been standard therapy, direct oral anticoagulants (DOACs) are increasingly adopted, yet real-world data in cancer-associated and non-cancer populations are limited. This study aimed to compare demographics, clinical features, therapeutic strategies, and outcomes between oncologic patients with acute PE (experimental group) and non-cancer patients with PE (control group). Methods: We performed a multicentric retrospective cohort study of adults admitted with acute PE between January 2019 and December 2021. The cohort comprised 120 non-cancer and 106 cancer patients. Standard management was low-molecular-weight heparin with transition to (VKA) or (DOAC), when not contraindicated. Data on demographics, comorbidities, and laboratory biomarkers (including NT-proBNP, threshold 600 pg/mL) were analyzed. Primary outcomes were early (≤30 days) and late (31–365 days) all-cause mortality. Secondary outcomes included PE recurrence and bleeding events. Results: Among 226 PE patients (non-oncological n = 120; oncological n = 106), the cancer group was older (69.2 ± 12.6 vs. 62.6 ± 17.3 years; p = 0.001) with similar ECG findings and hemodynamic stability at presentation. NT-proBNP > 600 pg/mL was more frequent in cancer (37.7% vs. 23.3%; p = 0.018), whereas D-dimer > 5 mg/L was more common in non-cancer (74.2% vs. 55.7%; p = 0.003). DOAC use was lower in cancer patients (40.6% vs. 65.0%; p < 0.001). Early mortality was comparable (17.9% vs. 13.3%; p = 0.341), but late mortality was higher in the cancer patient subgroup (38.7% vs. 3.3%; p < 0.001). In multivariable analysis, belonging to the cancer subgroup was associated with NT-proBNP ≥ 600 (OR 2.08, 95% CI 1.08–4.01; p = 0.029) and older age (OR 1.025 per year, 95% CI 1.005–1.045; p = 0.016), and inversely associated with D-dimer > 5 mg/L (OR 0.35, 95% CI 0.19–0.64; p < 0.001). Conclusions: Prompt anticoagulation was associated with lower early mortality, while differences in late mortality appeared to be largely confounded by age and cancer status. NT-proBNP may serve as a useful risk-stratification biomarker, but confirmation in larger, prospective studies is required. Full article
(This article belongs to the Special Issue Recent Advances in Pulmonary Embolism and Thrombosis: 2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop